UNSPSC 51241547: Polyethylene glycol/polyvinyl alcohol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.

UNSPSC 51241547 Polyethylene glycol/polyvinyl alcohol is a Commodity code under which state and local governments procure pharmaceutical-grade excipients and active pharmaceutical ingredients for use in generic and over-the-counter (OTC) drug formulations distributed through government healthcare and correctional facilities. The recent activity under this code reflects multistate cooperative purchasing vehicles sourcing finished or bulk pharmaceutical products rather than raw chemical inputs, with state departments of health, administration, and corrections as the primary issuing bodies alongside affiliated facility networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026. The RFP specifies distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), requires cGMP and Drug Supply Chain Security Act (DSCSA) certification, mandates contractual relationships with at least two of the three authorized wholesalers, and imposes a 3 percent administrative fee on all purchases. Evaluation weights pricing competitiveness at 75 percent, with secondary criteria covering fixed pricing (10 percent), EDI capability (5 percent), administrative fee format compliance (5 percent), and pricing flexibility options including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Awarded vendors become effective July 1, 2026, with a two-year initial contract term and optional extensions; the RFP does not disclose specific dollar values but establishes performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.